Jeffrey Katz, MD
Internal Medicine · Oxford, CTNPI 1780651745
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $360,000 of the $361,428 with a category attached, or 99.6%. Ascend Laboratories LLC accounts for 99.6% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $60,437, more than ten times the $228 reported in 2019. Among internal medicine clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 81 payments — averaging $4462.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ascend Laboratories LLC$360K
- Merck$770
- Lilly USA, LLC$123
- AstraZeneca$75
- Smith+Nephew$74
- AbbVie$63
- plus $322 from 10 others
What the payments were for
- Consulting fees$360,000100%
- Food & beverage$1,4280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ascend Laboratories LLC | 6 | $360,000 |
| Merck | 47 | $770 |
| Lilly USA, LLC | 5 | $123 |
| AstraZeneca | 3 | $75 |
| Smith+Nephew | 2 | $74 |
| AbbVie | 3 | $63 |
| GSK | 3 | $60 |
| Sumitomo Pharma America, Inc. | 2 | $57 |
| Astellas Pharma US Inc | 2 | $54 |
| Exact Sciences | 2 | $31 |
| Novo Nordisk | 1 | $25 |
| Hydrofera LLC | 1 | $24 |
| Corcept Therapeutics | 1 | $23 |
| Eisai Inc. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
How this compares
$361,428 in reported general payments places this provider in the 95th percentile of 2,067 internal medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 37 | $59,714 |
| EliquisApixaban | 33 | $54,071 |
| XareltoRivaroxaban | 22 | $24,871 |
| OzempicSemaglutide | 15 | $16,245 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $9,628 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 13 | $8,348 |
| Potassium Chloride | 40 | $8,244 |
| SynthroidLevothyroxine Sodium | 62 | $6,971 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 22 | $5,870 |
| Nebivolol Hcl | 85 | $5,736 |
| Atorvastatin Calcium | 305 | $3,057 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $2,882 |
| Rosuvastatin Calcium | 282 | $2,847 |
| Metoprolol Succinate | 170 | $2,626 |
| Olmesartan Medoxomil | 172 | $2,471 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $770 | $59,71437 claims |
| Novo NordiskOzempic | $25 | $16,24515 claims |
| AbbVieSynthroid | $63 | $6,97162 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $2,129165 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,067 internal medicine providers in Connecticut.
Other internal medicine in Oxford
- Steven RyderWestport$3.9M
- Nancy BrownNew Haven$1.6M
- Arthur DecillisMadison$1M
- Charles MontanoCromwell$970K
- Gary BlickNorwalk$683K
- Scott GottliebStamford$508K
- Nicholas DainiakBridgeport$352K
- Thomas PellechiGreenwich$196K
- John PriceGlastonbury$188K
- Richard LiftonNew Haven$160K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.